HomeAbout UsHistory
ABL Bio History
History of ABL Bio
2022
12
First dosed in Phase 1 clinical trial of ABL301
11
Article about ABL301 published in Cell Reports Methods
05
Article about ABL501 published in Molecular Therapy
03
ABL111 received Orphan-Drug Designation
01
Signs licensing agreement with Sanofi
2021
12
re-certified as Korea Innovative Pharmaceutical Company
08
ABL501 Phase 1 clinical trial IND approved by MFDS
07
Review paper on bispecific antibody-based immunotherapy published in Vaccines
06
First patient dosed in Phase 1 clinical trial of ABL111
04
First patient dosed in Phase 1 clinical trial of ABL503
03
ABL111 phase 1 clinical trial IND approved by U.S. FDA
02
ABL001 Phase 1 clinical trial IND approved by MFDS
01
ABL503 Phase 1 clinical trial IND approved by U.S. FDA
01
ABL's 4-1BB bispecific antibody introduced in 'Science Advances'
01
ABL001 research published in International Journal of Molecular Sciences
2020
11
ABL and LegoChem sign MOU to expand areas of ADC collaboration
10
ABL and LegoChem sign licensing agreement with CStone Pharmaceuticals
04
ABL501 designated as National Project
04
Signs MOU with Samsung Medical Center for development of cancer immunotherapy
03
ABL001 Phase 1b/2a clinical trial approved by MFDS
2019
02
Signs licensing agreement with WuXi Biologics
11
Signs licensing agreement GenScript Biologics
11
Signs licensing agreement with DKFZ
04
Signs licensing agreement with TSD Life Sciences
01
Signs MOU with Genome & Company for development of immune checkpoint inhibitors
2018
12
ABL Bio IPO on KOSDAQ
11
Signs licensing agreement with TRIGR Therapeutics for ABL001
09
Signs licensing agreement with Yuhan
08
Signs joint development and licensing agreement with Dt&SanoMedics
07
Signs licensing agreement with TRIGR Therapeutics
07
Signs joint development and licensing agreement with I-Mab Biopharma
06
Series C Funding (70 billion KRW)
01
Signs licensing agreement with Dong-A ST
2017
08
ABL001 Phase 1 clinical trial IND approved by MFDS
03
Series B Funding (20 billion KRW)
2016
03
Series A Funding (9 billion KRW)
02
Establishment of ABL Bio